Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2013

View Archived Issues

Epizyme presents novel epigenetic-targeted, small-molecule anticancer agents

Researchers present updated results for CART-19 cell therapy

Exploration of a key mechanistic pathway of antiapoptotic signaling in multiple myeloma

German and U.S. researchers design novel transgenic rat model for Huntington's disease

Novel agents for heart failure presented by German researchers

Novo Nordisk discloses new ligands binding to IL-21

New labeled NMDA receptor ligands patented by group in The Netherlands

Merz Pharma presents novel NMDA glycine B receptor antagonists

Novel monoclonal antibodies divulged by Antitope

Theravance synthesizes new series of neprilysin inhibitors

TRU-016 receives orphan medicinal product designation in Europe for CLL

Probuphine obtains FDA priority review designation for opioid dependence

Synergy Pharmaceuticals reports data from phase IIb/III plecanatide trial

Phase II SGI-110 trial begins in hepatocellular carcinoma

Photocure receives payment for Lumacan from Salix Pharmaceuticals

AbbVie launched as independent biopharmaceutical company

Phase IIb data presented for vaccine against enterotoxigenic bacteria

Small-molecule FADK inhibitor demonstrates efficacy for brain cancers

Results from a first-in-human phase I trial presented for AR-42

Kareus Therapeutics announces commencement of phase I trial for Alzheimer's disease candidate

Nexavar meets primary endpoint in RAI-refractory differentiated thyroid cancer

Clinical hold lifted for OncoMed's demcizumab

FDA deems complete Merck & Co's resubmission of NDA for ezetimibe/atorvastatin tablets

Relypsa reaches agreement with FDA for phase III trial of patiromer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 23, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...